We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...

Uptake of continuous glucose monitoring (CGM) was relatively low among vulnerable diabetes patients in the largest national ...

Inspired by the jets of water that squids use to propel themselves through the ocean, a team developed an ingestible capsule that releases a burst of drugs directly into the lining of the stomach or ...

EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...

Embracing industrial symbiosis goes beyond ethical responsibility; it’s a chance for companies to lower costs, reduce ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

Novo Nordisk's (NVO) contract Ypsomed to supply the company with injection pens designed to deliver its next-gen obesity ...

Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source ...

Thermo Fisher has launched a suite of expanded CRO and CDMO services under its own brand, Accelerator™ Drug Development, intended to serve biotechs and pharmas.

According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...

As far as competition goes, Eli Lilly is one of the two current leaders in the weight loss space, along with Novo Nordisk.